Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of amivantamab after definitive concurrent platinum-based chemoradiotherapy for unresectable locally advanced head and neck squamous cell carcinoma
MOH_2026-10-07_017067Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Amivantamab with Observation (standard of care) (2 arms). Primary endpoint: Event-free survival. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
amivantamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2026-10-07_017067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-10-07_017067.